MUC1 in hematological malignancies

References

• Backstrom M, Link T, Olson FJ, et al. Recombinant MUC1 mucin with a breast cancer-like O-glycosylation produced in large amounts in Chinese-hamster ovary cells. Biochem J. 2003;376:677–686.
   PubMed Web of Science ®Google Scholar
• Brockhausen I, Yang JM, Burchell J, et al. Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. Eur J Biochem. 1995;233:607–617.
   PubMedGoogle Scholar
• Li Y, Liu D, Chen D, et al. Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene. 2003;22:6107–6110.
   PubMed Web of Science ®Google Scholar
• Raina D, Agarwal P, Lee J, et al. Characterization of the MUC1-C Cytoplasmic Domain as a Cancer Target. PLoS One. 2015;10:e0135156.
   Google Scholar
• Raina D, Kosugi M, Ahmad R, et al. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Ther. 2011;10:806–816.
   PubMed Web of Science ®Google Scholar
• Rajabi H, Ahmad R, Jin C, et al. MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells. Prostate. 2012;72:1659–1668.
   PubMed Web of Science ®Google Scholar
• Ye Q, Yan Z, Liao X, et al. MUC1 induces metastasis in esophageal squamous cell carcinoma by upregulating matrix metalloproteinase 13. Lab Invest. 2011;91:778–787.
   PubMed Web of Science ®Google Scholar
• Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 2009;9:874–885.
   PubMed Web of Science ®Google Scholar
• Kufe DW. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene. 2013;32:1073–1081.
   PubMed Web of Science ®Google Scholar
• Jain S, Stroopinsky D, Yin L, et al. Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. Blood. 2015;126:354–362.
   PubMed Web of Science ®Google Scholar
• Brossart P, Schneider A, Dill P, et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res. 2001;61:6846–6850.
   PubMed Web of Science ®Google Scholar
• Cloosen S, Gratama J, van Leeuwen EB, et al. Cancer specific Mucin-1 glycoforms are expressed on multiple myeloma. Br J Haematol. 2006;135:513–516.
   PubMed Web of Science ®Google Scholar
• Hasegawa H, Komoda M, Yamada Y, et al. Aberrant overexpression of membrane-associated mucin contributes to tumor progression in adult T-cell leukemia/lymphoma cells. Leuk Lymphoma. 2011;52:1108–1117.
   PubMed Web of Science ®Google Scholar
• Kawano T, Ahmad R, Nogi H, et al. MUC1 oncoprotein promotes growth and survival of human multiple myeloma cells. Int J Oncol. 2008;33:153–159.
   PubMed Web of Science ®Google Scholar
• Schlom J. The MUC1-C oncoprotein as a target in hematologic malignancies. Cancer Biol Ther. 2010;10:492–494.
   PubMed Web of Science ®Google Scholar
• Stroopinsky D, Rosenblatt J, Ito K, et al. MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells. Cancer Res. 2013;73:5569–5579.
   PubMed Web of Science ®Google Scholar
• Yin L, Ahmad R, Kosugi M, et al. Survival of human multiple myeloma cells is dependent on MUC1 C-terminal transmembrane subunit oncoprotein function. Mol Pharmacol. 2010;78:166–174.
   PubMed Web of Science ®Google Scholar
• Yin L, Kufe D. MUC1-C oncoprotein blocks terminal differentiation of chronic myelogenous leukemia cells by a ROS-mediated mechanism. Genes Cancer. 2011;2:56–64.
   PubMedGoogle Scholar
• Fatrai S, Schepers H, Tadema H, et al. Mucin1 expression is enriched in the human stem cell fraction of cord blood and is upregulated in majority of the AML cases. Exp Hematol. 2008;36:1254–1265.
   PubMed Web of Science ®Google Scholar
• Kufe DW. Functional targeting of the MUC1 oncogene in human cancers. Cancer Biol Ther. 2009;8:1197–1203.
   PubMed Web of Science ®Google Scholar
• Liu S, Yin L, Stroopinsky D, et al. MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells. Blood. 2014;123:734–742.
   PubMed Web of Science ®Google Scholar
• Schroeder JA, Adriance MC, Thompson MC, et al. MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion. Oncogene. 2003;22:1324–1332.
   PubMed Web of Science ®Google Scholar
• Huang L, Chen D, Liu D, et al. MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin. Cancer Res. 2005;65:10413–10422.
   PubMed Web of Science ®Google Scholar
• Ahmad R, Raina D, Joshi MD, et al. MUC1-C oncoprotein functions as a direct activator of the nuclear factor-kappaB p65 transcription factor. Cancer Res. 2009;69:7013–7021.
   PubMed Web of Science ®Google Scholar
• Ren J, Agata N, Chen D, et al. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell. 2004;5:163–175.
   PubMed Web of Science ®Google Scholar
• Ren J, Bharti A, Raina D, et al. MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90. Oncogene. 2006;25:20–31.
   PubMed Web of Science ®Google Scholar
• Ahmad R, Alam M, Rajabi H, et al. The MUC1-C oncoprotein binds to the BH3 domain of the pro-apoptotic BAX protein and blocks BAX function. J Biol Chem. 2012;287:20866–20875.
   PubMed Web of Science ®Google Scholar
• Alam M, Rajabi H, Ahmad R, et al. Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells. Oncotarget. 2014;5:2622–2634.
   PubMed Web of Science ®Google Scholar
• Sahraei M, Roy LD, Curry JM, et al. MUC1 regulates PDGFA expression during pancreatic cancer progression. Oncogene. 2012;31:4935–4945.
   PubMed Web of Science ®Google Scholar
• Nath S, Daneshvar K, Roy LD, et al. MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes. Oncogenesis. 2013;2:e51.
   PubMed Web of Science ®Google Scholar
• Raina D, Uchida Y, Kharbanda A, et al. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells. Oncogene. 2014;33:3422–3431.
   PubMed Web of Science ®Google Scholar
• Michal Bar-Natan KL, Coll MD, Stroopinsky D, et al., editors. Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1. Blood (Suppl). 2014;124:Abstract 3378.
   Google Scholar
• Dyomin VG, Palanisamy N, Lloyd KO, et al. MUC1 is activated in a B-cell lymphoma by the t(1;14)(q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets. Blood. 2000;95:2666–2671.
   PubMed Web of Science ®Google Scholar
• Yin L, Wu Z, Avigan D, et al. MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells. Blood. 2011;117:4863–4870.
   PubMed Web of Science ®Google Scholar
• Kawano T, Ito M, Raina D, et al. MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells. Cancer Res. 2007;67:11576–11584.
   PubMed Web of Science ®Google Scholar
• Yin L, Ahmad R, Kosugi M, et al. Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein. Cancer Biol Ther. 2010;10:483–491.
   PubMed Web of Science ®Google Scholar
• Yin L, Li Y, Ren J, et al. Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J Biol Chem. 2003;278:35458–35464.
   PubMed Web of Science ®Google Scholar
• Yin L, Kosugi M, Kufe D. Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH. Blood. 2012;119:810–816.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Rajabi H, Kufe D. Mucin 1 C-terminal subunit oncoprotein is a target for small-molecule inhibitors. Mol Pharmacol. 2011;79:886–893.
   PubMed Web of Science ®Google Scholar
• Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013;12:931–947.
   PubMed Web of Science ®Google Scholar
• Bensaad K, Tsuruta A, Selak MA, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006;126:107–120.
   PubMed Web of Science ®Google Scholar
• Yin L, Kufe T, Avigan D, et al. Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death. Blood. 2014;123:2997–3006.
   PubMed Web of Science ®Google Scholar
• Luisi-DeLuca C, Mitchell T, Spriggs D, et al. Induction of terminal differentiation in human K562 erythroleukemia cells by arabinofuranosylcytosine. J Clin Invest. 1984;74:821–827.
   PubMed Web of Science ®Google Scholar
• Konopleva M, Tsao T, Ruvolo P, et al. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood. 2002;99:326–335.
   PubMed Web of Science ®Google Scholar
• Rajabi H, Ahmad R, Jin C, et al. MUC1-C oncoprotein induces TCF7L2 transcription factor activation and promotes cyclin D1 expression in human breast cancer cells. J Biol Chem. 2012;287:10703–10713.
   PubMed Web of Science ®Google Scholar
• Bouillez A, Rajabi H, Pitroda S, et al. Inhibition of MUC1-C suppresses MYC expression and attenuates malignant growth in KRAS mutant lung adenocarcinomas. Cancer Res. 2016;76:1538–1548.
   PubMed Web of Science ®Google Scholar
• Ysebaert L, Chicanne G, Demur C, et al. Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia. 2006;20:1211–1216.
   PubMed Web of Science ®Google Scholar
• Wang Y, Krivtsov AV, Sinha AU, et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science. 2010;327:1650–1653.
   PubMed Web of Science ®Google Scholar
• Tagde A, Rajabi H, Bouillez A, et al. MUC1-C drives MYC in multiple myeloma. Blood. 2016;127:2587–2597.
   PubMed Web of Science ®Google Scholar
• Rosnet O, Buhring HJ, Marchetto S, et al. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia. 1996;10:238–248.
   PubMed Web of Science ®Google Scholar
• Raina D, Ahmad R, Kumar S, et al. MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. EMBO J. 2006;25:3774–3783.
   PubMed Web of Science ®Google Scholar
• Li Y, Kuwahara H, Ren J, et al. The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin. J Biol Chem. 2001;276:6061–6064.
   PubMed Web of Science ®Google Scholar
• Li Y, Bharti A, Chen D, et al. Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin. Mol Cell Biol. 1998;18:7216–7224.
   PubMed Web of Science ®Google Scholar
• Ramasamy S, Duraisamy S, Barbashov S, et al. The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop. Mol Cell. 2007;27:992–1004.
   PubMed Web of Science ®Google Scholar
• Li Y, Ren J, Yu W, et al. The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin. J Biol Chem. 2001;276:35239–35242.
   PubMed Web of Science ®Google Scholar
• Li Y, Yu WH, Ren J, et al. Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein. Mol Cancer Res. 2003;1:765–775.
   PubMed Web of Science ®Google Scholar
• Wei X, Xu H, Kufe D. Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell. 2005;7:167–178.
   PubMed Web of Science ®Google Scholar
• Wei X, Xu H, Kufe D. MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. Mol Cell. 2006;21:295–305.
   PubMed Web of Science ®Google Scholar
• Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008;112:4808–4817.
   PubMed Web of Science ®Google Scholar
• Lowenberg B. Minimal residual disease in chronic myeloid leukemia. N Engl J Med. 2003;349:1399–1401.
   PubMed Web of Science ®Google Scholar
• Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5:172–183.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046–1060.
   PubMed Web of Science ®Google Scholar
• Kuhn DJ, Berkova Z, Jones RJ, et al. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood. 2012;120:3260–3270.
   PubMed Web of Science ®Google Scholar
• Myrna Rita Nahas DS, Rajabi H, Tagde A, et al. MUC1 inhibition overcomes chemotherapy resistance in acute myeloid leukemia. Blood (Suppl). 2015;126:Abstract 2473.
   Google Scholar
• Brossart P, Heinrich KS, Stuhler G, et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood. 1999;93:4309–4317.
   PubMed Web of Science ®Google Scholar
• Pol J, Bloy N, Buque A, et al. Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology. 2015;4:e974411
   PubMed Web of Science ®Google Scholar
• Tarp MA, Sorensen AL, Mandel U, et al. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. Glycobiology. 2007;17:197–209.
   PubMed Web of Science ®Google Scholar
• Rivalland G, Loveland B, Mitchell P. Update on Mucin-1 immunotherapy in cancer: a clinical perspective. Expert Opin Biol Ther. 2015;15:1773–1787.
   PubMed Web of Science ®Google Scholar
• Arlen PM, Gulley JL, Madan RA, et al. Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. Crit Rev Immunol. 2007;27:451–462.
   PubMed Web of Science ®Google Scholar
• Carmon L, Avivi I, Kovjazin R, et al. Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients. Br J Haematol. 2015;169:44–56.
   PubMed Web of Science ®Google Scholar
• Gong J, Chen D, Kashiwaba M, et al. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci USA. 1998;95:6279–6283.
   PubMed Web of Science ®Google Scholar
• Gong J, Koido S, Chen D, et al. Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood. 2002;99:2512–2517.
   PubMed Web of Science ®Google Scholar
• Avigan D. Dendritic cell-tumor fusion vaccines for renal cell carcinoma. Clin Cancer Res. 2004;10:6347S–6352S.
   PubMed Web of Science ®Google Scholar
• Avigan DE, Vasir B, George DJ, et al. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother. 2007;30:749–761.
   PubMed Web of Science ®Google Scholar
• Rosenblatt J, Avivi I, Vasir B, et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res. 2013;19:3640–3648.
   PubMed Web of Science ®Google Scholar
• Rosenblatt J, Vasir B, Uhl L, et al. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood. 2011;117:393–402.
   PubMed Web of Science ®Google Scholar
• Jacalyn Rosenblatt RMS, Uhl L, Neuberg D, et al. DC/Aml fusion cell vaccination administered to AML patients who achieve a complete remission potently expands leukemia reactive T cells and is associated with durable remissions. Blood (Suppl). 2015;126:Abstract 2549.
   Google Scholar